Cancer research on immune evasion and cell survival

Recent scientific developments have highlighted new mechanisms used by cancer cells to evade treatment and the immune system. Researchers at the Walter and Eliza Hall Institute (WEHI) in Australia identified gamma delta (γδ) T cells that can recognize and attack small cell lung cancer (SCLC), a highly aggressive disease that often remains ‘invisible’ to conventional immune cells. The study suggests that existing medications might be used to enhance these cells' ability to destroy tumors, potentially offering new immunotherapy options.

Detailed findings published in the journal Cancer Cell indicate that SCLC, which accounts for 10% to 15% of lung cancer cases and has a five-year survival rate of less than 7%, often evades detection by suppressing molecules used by conventional T cells. However, gamma delta T cells use alternative biological signals to detect cellular stress. Laboratory experiments using miniature tumor models demonstrated these cells successfully killing cancer cells, and patients with higher levels of these cells in their tumors tend to have longer survival rates.

Research into enhancing this response identified that tarlatamab, a treatment for SCLC, and zoledronate, a medicine for bone conditions, may support the immune attack through different mechanisms. These findings could lead to new adoptive cell therapies where a patient’s own gamma delta T cells are collected, multiplied, and reintroduced to fight the tumor.

Complementary research from Trinity College Dublin found that cancer cells can enter a “zombie-like state” called premature senescence to survive chemotherapy. Additionally, scientists discovered that Inhibitor of Apoptosis Proteins (IAPs) allow tumors to escape cell-killing effects by neutralizing ‘Death Receptors’ triggered by DNA damage.